1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL
Reports Second Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics Stockholders Elect Douglas W. Calder and Corey Watton
Reports First Quarter 2026 Financial Results and Corporate Update
Material Contracts, End of Material Contract, Reg. FD
.2 Appoints Justin Renz as Chief Financial Officer
Timothy Sangiovanni Appointed Interim Principal Financial Officer
Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Announces CFO Transition
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus Filed Pursuant to Rule 424(b)(2)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Contested Proxy Solicitation Materials
PRRN14A
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Submission Upload
Correspondence